Ticker

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Galera Therapeutics, Inc. (OTC: GRTX) and Obsidian Therapeutics, Inc. Upon closing of the proposed transaction, Galera shareholders are expected to own approximately 1.8% of the combined company.Halper Sadeh encourages Galera shareholders to click here to learn more about their rights and options or contact…

CAMBRIDGE, Mass. and MALVERN, Pa., April 14, 2026 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor through clinical development for patients with the hardest-to-treat forms of advanced breast cancer, and Obsidian Therapeutics, Inc. (“Obsidian”), a privately-held clinical-stage biopharmaceutical company harnessing…

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Galera Therapeutics, Inc. (OTCMKTS:…

CAMBRIDGE, Mass. & MALVERN, Pa.--(BUSINESS WIRE)--Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor through clinical development for patients with the hardest-to-treat forms of advanced breast cancer, and Obsidian Therapeutics, Inc. (“Obsidian”), a privately-held clinical-stage biopharmaceutical company harnessing novel…

Risk and Volatility Galera Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500. Valuation and Earnings This table compares Galera Therapeutics and Athersys"s gross revenue,